GSK : Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
For media and investors only Issued: London UK Primary vaccination with Beta-containing vaccine candidate delivers 64.7% efficacy against symptomatic... | June 24, 2022